en.wikipedia.org/wiki/David_Baker_(biochemist)
3 corrections found
Prospect Genomics which was acquired by an Eli Lilly subsidiary in 2001
Prospect Genomics was not acquired by a Lilly subsidiary in 2001. It was acquired by Structural GenomiX/SGX in May 2001, and Lilly moved to acquire SGX later, in 2008.
Full reasoning
A 2006 SEC filing by SGX Pharmaceuticals states: "In 1999, Dr. Burley co-founded Prospect Genomics, Inc. ... that we acquired in May 2001." That directly identifies SGX/Structural GenomiX as the 2001 acquirer of Prospect Genomics.
A separate 2008 Lilly announcement says "Lilly to Acquire SGX Pharmaceuticals" and is dated July 8, 2008. So Lilly's acquisition activity involved SGX in 2008, not Prospect Genomics in 2001.
Therefore, the article's wording is incorrect: Prospect Genomics was acquired by SGX/Structural GenomiX in 2001, not by an Eli Lilly subsidiary in 2001.
2 sources
- SGX Pharmaceuticals, Inc. (SEC filing)
In 1999, Dr. Burley co-founded Prospect Genomics, Inc., a San Francisco-based drug discovery company that we acquired in May 2001.
- Lilly to Acquire SGX Pharmaceuticals
Date: July 8, 2008 ... Eli Lilly and Company and SGX Pharmaceuticals, Inc. ... announced that the companies have signed a definitive merger agreement providing for the acquisition of SGX in an all-cash transaction.
Icosavax which was acquired by AstraZeneca in 2023
AstraZeneca agreed to buy Icosavax in 2023, but the acquisition was completed in 2024. So the article's acquisition year is wrong.
Full reasoning
Icosavax's own December 2023 announcement says it had entered into a definitive agreement to be acquired by AstraZeneca and that the deal was expected to close in the first quarter of 2024.
AstraZeneca then announced on February 19, 2024 that the acquisition of Icosavax was completed.
So 2023 was the year the deal was announced/agreed, not the year the acquisition was completed.
2 sources
- Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Icosavax, Inc. today announced it has entered into a definitive agreement ... Subject to the satisfaction of the conditions in the merger agreement, the acquisition is expected to close in the first quarter of 2024.
- AstraZeneca completes acquisition of Icosavax
19 February 2024 ... AstraZeneca announced today the successful completion of the acquisition of Icosavax, Inc.
TED's Audacious Prize
TED does not list an award called the 'Audacious Prize.' TED says the TED Prize became The Audacious Project in 2018, and UW describes Baker's institute as receiving support through The Audacious Project.
Full reasoning
This wording appears to misname Baker's TED-related recognition.
TED's official page says "In 2018, the TED Prize became: The Audacious Project" and describes The Audacious Project as a funding initiative, not a prize called the "Audacious Prize."
The University of Washington's Institute for Protein Design likewise says the institute received "support through The Audacious Project" and that, on April 16, 2019, the IPD "was named an Audacious Project at TED2019."
So Baker/IPD was associated with The Audacious Project, but the article's label "TED's Audacious Prize" is not the official TED name for that program.
3 sources
- TED Prize
In 2018, the TED Prize became: The Audacious Project, a new model to launch big, inspiring ideas with the potential to affect millions of lives.
- Audacious Project - Institute for Protein Design
With a solid blueprint in place and support through The Audacious Project, the IPD will venture to accelerate the pace of discovery ...
- Institute for Protein Design Audacious project facts - UW Medicine | Newsroom
On April 16, 2019, the IPD was named an Audacious Project at TED2019.